Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.